Slide 1: Q2 2023 Earnings and Business Update Call
Q2 2023 Earnings and Business Update Call Sanara MedTech Evidence Based Healing
Slide 2: Disclaimers
Sanara MedTech Disclaimers ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to ‘Sanara MedTech Inc. (the “Company,” *Sanara,” “we,” our" or“us") All s
Slide 3: Commentary on Q2 2023
Sanara MedTech Commentary on Q2 2023 + Financial Update + Highest net revenue quarter in the Company's history ($15.8 million). + Loss before income taxes narrowed from $3.4 million to $1.9 million in Q2 YOY. + Net loss of $1.9 million in Q2 2023 compared to $0.8 million of net income in Q2 2022. Th
Slide 4: Surgical Sales
Sanara MedTech Surgical Sales Sales Overview + Our products were sold in over 950 hospitals/ASCs across 33 states'*) in the TTM + Our products were contracted or approved to be sold in more than 3,000 hospitals/ASCs as of June 30, 2023 © Coneraes, =f — Q2 increase over Q1 was due to an agreement sig
Slide 5: Surgical Sales (continued)
Sanara MedTech Surgical Sales (continued) Sales Overview + Actions taken and future plans to address the slow down in revenue growth include: - Hiring increased in Q1 and is expected to continue through the end of the year in accordance with our plan - Vetting and training of new hires has improved
Slide 6: Value-Based Post Acute Wound Care Strategy
Sanara MedTech Value-Based Post Acute Wound Care Strategy Overview + Sam Muppalla, an experienced wound care executive in the post acute market, hired to lead this initiative. + We have developed a detailed value-based strategy and received initial validation from the market. — This strategy will in
Slide 7: Launch Details
Launch Details + Product is 510(k) cleared and product launch is estimated to occur in mid- Q4 2023. + Manufacturing runs have been scheduled * Currently being tested by clinical partners to ensure a smooth launch and adoption within key facilities BIASURGE -— Product Launch Sanara MedTech BIASona”
Slide 8: Collagen Products Asset Acquisition
Collagen Products Asset Acquisition Sanara MedTech Total initial consideration of $15.25 + Assets acquired from the sellers include: + Four 510(k) cleared collagen- based wound care products including CellerateRX and HYCOL. + Three new collagen-based products currently under development. + Nine pate
Slide 9: Q2 2023 Financial Highlights
Sanara MedTech Q2 2023 Financial Highlights Overview + Revenue + For the three months ended June 30, 2023, we generated net revenues of $15.8 million compared to net revenues of $9.7 million for the three months ended June 30, 2022, a 63% increase from the prior year period. + For the six months end
Slide 10: 2023 Financial Highlights (Continued)
Sanara MedTech 2023 Financial Highlights (Continued) Overview (Continued) + R&D Expenses + R&D expenses for the three months ended June 30, 2023, were $1.2 million compared to $1.1 million for the three months ended June 30, 2022. + R&D expenses for the six months ended June 30, 2023, were $2.5 mill
Slide 11: Questions
iit Questions Sanara MedTech Evidence Based Healing